Yesterday afternoon, Telix Pharmaceuticals Ltd (ASX: TLX) reported US$206 million in unaudited group revenue for Q3 2025, up 53% year-over-year, and upgraded its FY 2025 revenue guidance to US$800–820 million.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Q3 2025 unaudited group revenue of US$206 million, up 53% year-on-year
- PSMA imaging revenue of US$155 million for the quarter
- FY 2025 revenue guidance lifted to US$800–820 million (previously US$770–800 million)
- Gozellix® now fully reimbursed by US Centers for Medicare and Medicaid Services
- Illuccix® approved and launching in 19 European markets and the UK
- Major clinical milestones across prostate, kidney, and brain cancer programs
What else do investors need to know?
Telix continues to invest in its pipeline, including advancing Phase 3 trials for its lead prostate cancer therapy (TLX591) and launching international studies in kidney and brain cancer. The company completed its final royalty payment for the Illuccix® technology, giving full freedom to operate on global sales.
The group's manufacturing facilities in Australia and Japan have reached the final stages of fit-out and licensing. This supports future product supply as the company scales production for new approvals and market launches.
What did Telix Pharmaceuticals management say?
Commenting on the announcement, Managing Director and Group CEO Dr Christian Behrenbruch said:
We believe this is a solid result, particularly in light of the reimbursement dynamics during the quarter. Moreover, a 3% increase in dose volumes suggests competitive pricing pressures are beginning to stabilize. Telix has entered Q4 in a position of strength, supported by a growing customer base, two FDA-approved PSMA imaging agents and CMS reimbursement for Gozellix effective from 1 October in the U.S. This differentiated two-product strategy enables us to expand market share across all customer segments, with Gozellix enhancing our production flexibility and providing customer choice based on patient reimbursement pathways.
What's next for Telix Pharmaceuticals?
Looking ahead, Telix plans to deliver on its upgraded revenue guidance and expects increased R&D investment of 20% to 25% in FY 2025 versus FY 2024. Management is targeting expanded commercial rollouts, new product approvals, and further clinical progress in oncology and rare disease programs.
The business aims to leverage its dual product strategy and broader international manufacturing capabilities to strengthen its position in precision medicine for cancer diagnosis and therapy.
Telix Pharmaceuticals share price snapshot
The Telix Pharmaceuticals share price has fallen 33% in the past year, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.
